Therapeutics News and Research

RSS

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

18 Apr 2011

Nuvo Research to acquire ZARS Pharma

Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.

18 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Scientists develop new compound for multiple sclerosis treatment

Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models.

18 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis, today presented important efficacy data at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

New approach links cancer cell metabolism with poor clinical outcome

Identifying gene mutations in cancer patients to predict clinical outcome has been the cornerstone of cancer research for nearly three decades, but now researchers at the Kimmel Cancer Center at Jefferson have invented a new approach that instead links cancer cell metabolism with poor clinical outcome. This approach can now be applied to virtually any type of human cancer cell.

15 Apr 2011

Halozyme announces Aspart-PH20 study results in type 1 diabetes

Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.

15 Apr 2011

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

Pharmacy costs for multiple sclerosis patients increase at a faster rate than medical costs

Analysis of direct pharmacy and medical costs for patients with multiple sclerosis (MS) showed pharmacy costs are increasing at a slightly faster rate than medical costs, but new MS medications are expected to shift the majority of the direct health cost burden to pharmacy, according to a new study by Prime Therapeutics (Prime). The study will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn.

15 Apr 2011

Acute high-fat diets can protect against heart attack

Approximately one million Americans suffer a heart attack each year of which some 400,000 attacks are fatal. A key cause of heart attacks is atherosclerosis, a process in which cholesterol builds up in the arteries and impedes the ability of the blood to flow to our most vital organ.

15 Apr 2011

Researchers report injectable gel can help treat arthritis

Some 25 million people in the United States alone suffer from rheumatoid arthritis or its cousin osteoarthritis, diseases characterized by often debilitating pain in the joints. Now researchers at Brigham and Women's Hospital report an injectable gel that could spell the future for treating these diseases and others.

15 Apr 2011

Researchers show how TET1 enzyme controls fetal development and fights cancer

To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.

15 Apr 2011

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

A Taiwanese research team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University has partnered with a research group led by Dr. Dennis Whitefield from National Research Council of Canada to develop innovative cancer diagnostic and treatment technologies.

15 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

RXi Pharmaceuticals acquires Apthera

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.

15 Apr 2011

Echo awarded method patent for Symphony transdermal continuous glucose monitoring system

Echo Therapeutics, Inc., a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it received a notice of allowance for U.S. Patent Application No.11/275,038, "System and Method for Continuous Non-Invasive Glucose Monitoring," for the Symphony tCGM System.

12 Apr 2011

Sea squirt study unravels complex mechanisms underlying heart defects

Each year in the U.S., approximately 40,000 babies are born with a heart defect. Without the proper diagnosis and treatment, many of these babies would die before their first birthday, according to Dr. Scott Klewer, a cardiologist at the UA's College of Medicine.

12 Apr 2011

Researchers discover new cancer stem cells in breast tissue

Whitehead Institute researchers have discovered that a differentiated cell type found in breast tissue can spontaneously convert to a stem-cell-like state, the first time such behavior has been observed in mammalian cells.

12 Apr 2011